Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study
Paradoxically, patients with advanced stomach cancer who are Helicobacter pylori-positive (HP+) have a higher survival rate than those who are HP-. This finding suggests that HP infection has beneficial effects for cancer treatment. The present study examines whether HP+ individuals have a lower lik...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLOS Global Public Health |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022139/?tool=EBI |
| _version_ | 1797695303016513536 |
|---|---|
| author | Satoshi S. Nishizuka Masahiro Nakatochi Yuka Koizumi Asahi Hishida Rieko Okada Sayo Kawai Yoichi Sutoh Keisuke Koeda Atsushi Shimizu Mariko Naito Kenji Wakai |
| author_facet | Satoshi S. Nishizuka Masahiro Nakatochi Yuka Koizumi Asahi Hishida Rieko Okada Sayo Kawai Yoichi Sutoh Keisuke Koeda Atsushi Shimizu Mariko Naito Kenji Wakai |
| author_sort | Satoshi S. Nishizuka |
| collection | DOAJ |
| description | Paradoxically, patients with advanced stomach cancer who are Helicobacter pylori-positive (HP+) have a higher survival rate than those who are HP-. This finding suggests that HP infection has beneficial effects for cancer treatment. The present study examines whether HP+ individuals have a lower likelihood of death from cancer than those who are HP-. Prospective cohort data (n = 4,982 subjects enrolled in the DAIKO study between 2008–2010) were used to assess whether anti-HP antibody status was associated with cancer incidence. The median age in the primary registry was 53 years-old (range 35–69 years-old). Over the 8-year observation period there were 234 (4.7%) cancer cases in the cohort and 88 (1.8%) all-cause deaths. Urine anti-HP antibody data was available for all but one participant (n = 4,981; 99.98%). The number of HP+ and HP- individuals was 1,825 (37%) and 3,156 (63%), respectively. Anti-HP antibody distribution per birth year revealed that earlier birth year was associated with higher HP+ rates. With a birth year-matched cohort (n = 3,376), all-cancer incidence was significantly higher in HP+ individuals than those who were HP- (p = 0.00328), whereas there was no significant difference in the cancer death rate between HP+ and HP- individuals (p = 0.888). Cox regression analysis for prognostic factors revealed that the hazards ratio of HP+ was 1.59-fold (95%CI 1.17–2.26) higher than HP- in all-cancer incidence. Potential systemic effects of HP+ status may contribute to reduced likelihood of death for patients after an initial diagnosis of cancer. |
| first_indexed | 2024-03-12T03:10:27Z |
| format | Article |
| id | doaj.art-a1f5a8d1bd48459fadf2aa49eeb96c11 |
| institution | Directory Open Access Journal |
| issn | 2767-3375 |
| language | English |
| last_indexed | 2024-03-12T03:10:27Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLOS Global Public Health |
| spelling | doaj.art-a1f5a8d1bd48459fadf2aa49eeb96c112023-09-03T14:28:58ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752023-01-0132Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort studySatoshi S. NishizukaMasahiro NakatochiYuka KoizumiAsahi HishidaRieko OkadaSayo KawaiYoichi SutohKeisuke KoedaAtsushi ShimizuMariko NaitoKenji WakaiParadoxically, patients with advanced stomach cancer who are Helicobacter pylori-positive (HP+) have a higher survival rate than those who are HP-. This finding suggests that HP infection has beneficial effects for cancer treatment. The present study examines whether HP+ individuals have a lower likelihood of death from cancer than those who are HP-. Prospective cohort data (n = 4,982 subjects enrolled in the DAIKO study between 2008–2010) were used to assess whether anti-HP antibody status was associated with cancer incidence. The median age in the primary registry was 53 years-old (range 35–69 years-old). Over the 8-year observation period there were 234 (4.7%) cancer cases in the cohort and 88 (1.8%) all-cause deaths. Urine anti-HP antibody data was available for all but one participant (n = 4,981; 99.98%). The number of HP+ and HP- individuals was 1,825 (37%) and 3,156 (63%), respectively. Anti-HP antibody distribution per birth year revealed that earlier birth year was associated with higher HP+ rates. With a birth year-matched cohort (n = 3,376), all-cancer incidence was significantly higher in HP+ individuals than those who were HP- (p = 0.00328), whereas there was no significant difference in the cancer death rate between HP+ and HP- individuals (p = 0.888). Cox regression analysis for prognostic factors revealed that the hazards ratio of HP+ was 1.59-fold (95%CI 1.17–2.26) higher than HP- in all-cancer incidence. Potential systemic effects of HP+ status may contribute to reduced likelihood of death for patients after an initial diagnosis of cancer.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022139/?tool=EBI |
| spellingShingle | Satoshi S. Nishizuka Masahiro Nakatochi Yuka Koizumi Asahi Hishida Rieko Okada Sayo Kawai Yoichi Sutoh Keisuke Koeda Atsushi Shimizu Mariko Naito Kenji Wakai Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study PLOS Global Public Health |
| title | Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study |
| title_full | Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study |
| title_fullStr | Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study |
| title_full_unstemmed | Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study |
| title_short | Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study |
| title_sort | anti helicobacter pylori antibody status is associated with cancer mortality a longitudinal analysis from the japanese daiko prospective cohort study |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022139/?tool=EBI |
| work_keys_str_mv | AT satoshisnishizuka antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT masahironakatochi antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT yukakoizumi antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT asahihishida antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT riekookada antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT sayokawai antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT yoichisutoh antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT keisukekoeda antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT atsushishimizu antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT marikonaito antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy AT kenjiwakai antihelicobacterpyloriantibodystatusisassociatedwithcancermortalityalongitudinalanalysisfromthejapanesedaikoprospectivecohortstudy |